SCHEMBL10243952

SCHEMBL10243952

COC(=O)NCCNC(C)c1ccccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
TSHR P16473 2/20 0.41
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
MC4R P32245 1/20 0.39
ALOX15 P16050 1/20 0.37
LMNA P02545 1/20 0.37
MAPKAPK2 P49137 1/20 0.36
KCNA5 P22460 1/20 0.36
CES2 O00748 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CBR1 P16152 1/20 0.36
HTT P42858 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244611 0.85 HPGD (0.49) POLBLMNACES2HPGDSMN1; SMN2
SCHEMBL10244235 0.84 TSHR (0.43) TSHRMC4RLMNASMN1; SMN2HTT
SCHEMBL10244889 0.84 CA12 (0.40) TSHRLMNAKCNA5CBR1MTNR1A
SCHEMBL10243936 0.83 CA12 (0.40) TSHRCA12CA1CA2CA7
SCHEMBL10243808 0.82 HCRTR1 (0.50) TSHRLMNACES2HPGDSMN1; SMN2
SCHEMBL10244519 0.81 MTNR1A (0.43) POLBTSHRLMNAHPGDSMN1; SMN2
SCHEMBL10243950 0.80 ALDH1A1 (0.53) POLBTSHRLMNAHPGDSMN1; SMN2
SCHEMBL10244860 0.79 RRM1 (0.35) TSHRLMNASMN1; SMN2HTTALDH1A1
SCHEMBL5306681 0.78 GABRA1 (0.48) POLBTSHRGABRA1GABRB2LMNA
SCHEMBL4135919 0.76 POLB (0.62) POLBTSHRGABRA1GABRB2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 POLB 3348/4885TSHR 1567/4885GABRA1 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.